Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.

摘要: Optimal animal models of muscle invasive bladder cancer (MIBC) are necessary to overcome the current lack novel targeted therapies for this malignancy. Here we report on establishment and characterization patient-derived primary xenografts (PDX). Patient tumors were grafted under renal capsule mice subsequently transplanted over multiple generations. tumor PDX processed analysis copy number variations by aCGH, gene expression microarray, target pathways immunohistochemistry (IHC). One harbouring an FGFR3 mutation was treated with inhibitory monoclonal antibody targeting FGFR3. Five successfully established. Tumor doubling time ranged from 5 11 days. Array CGH revealed shared chromosomal aberrations in patient PDX. Gene microarray IHC confirmed that PDXs maintain similar patterns parental tumors. growth inhibited inhibitor. recapitulate biology patients' which they derived. Investigations related drug testing these therefore more likely be relevant disease state patients. They represent a valuable tool developing precision therapy MIBC.